Hcmed
TWO: 6934.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason Cheng
- Employees
- 61
- Headquarters
- Taipei, Taiwan
- IPO year
- 2024
- Market cap
- NT$5.6B
- Website
- http://www.hcmed-inno.com
Loading 6934…
Loading profile data…Frequently asked questions about 6934
What does Hcmed (6934.TWO) do?
HCmed Innovations Co Ltd. provides platforms for inhalation therapy using mesh technology. Its products include Pulmogine and AdheResp. The firm offers comprehensive aerosol characterization analytical services to support the development and optimization of inhalation products. It also offers analytical support in compliance with Pharmacopoeia g...
Where does 6934.TWO trade?
Hcmed (6934.TWO) trades on the Taipei Exchange.
What sector is 6934.TWO in?
Hcmed (6934.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hcmed?
Jason Cheng is the chief executive officer of Hcmed (6934.TWO).
Where is Hcmed headquartered?
Hcmed is headquartered in Taiwan.
Does 6934.TWO pay a dividend?
Hcmed (6934.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6934.TWO go public?
Hcmed (6934.TWO) completed its initial public offering in 2024.